Ultragenyx Pharmaceutical Inc.
RARENasdaqCIK 1515673HealthcareFiscal year ends Dec 31
Reports and events: 286 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1909:00 ET | 8-K | 8.01 Other events | 0001193125-26-424739 |
| 2026-10-1409:00 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-26-421079 |
| 2026-10-0709:00 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-26-416251 |
| 2026-09-1715:55 ET | 8-K | 8.01 Other events | 0001515673-26-000006 |
| 2026-09-0216:04 ET | 8-K | 8.01 Other events | 0001193125-26-380165 |
| 2026-08-1917:24 ET | 8-K | 8.01 Other events | 0001193125-26-357185 |
| 2026-08-1108:30 ET | 8-K | 8.01 Other events | 0001193125-26-343525 |
| 2026-08-0518:07 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-333233 |
| 2026-08-0416:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-332802 |
| 2026-05-1814:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-228639 |
| 2026-05-0618:18 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-206960 |
| 2026-05-0516:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-206368 |
| 2026-04-0208:45 ET | 8-K | 8.01 Other events | 0001193125-26-139084 |
| 2026-03-3008:45 ET | 8-K | 8.01 Other events | 0001193125-26-130498 |
| 2026-03-2716:30 ET | DEF 14A | Proxy statementPeriod 2026-05-14 | 0001308179-26-000174 |
| 2026-03-1208:45 ET | 8-K | 8.01 Other events | 0001193125-26-103167 |
| 2026-02-2308:45 ET | 8-K | 8.01 Other events | 0001193125-26-062568 |
| 2026-02-1816:59 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-057329 |
| 2026-02-1216:11 ET | 8-K | 2.02 Results of operations; 2.05 Exit or disposal costs; 9.01 Financial statements and exhibits | 0001193125-26-048738 |
| 2026-02-0308:15 ET | 8-K | 8.01 Other events | 0001193125-26-034474 |
| 2026-01-3008:45 ET | 8-K | 8.01 Other events | 0001193125-26-030590 |
| 2026-01-1207:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-009791 |
| 2025-12-3016:11 ET | 8-K | 8.01 Other events | 0001193125-25-337099 |
| 2025-12-2908:45 ET | 8-K | 8.01 Other events | 0001193125-25-332422 |
| 2025-11-0518:09 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-265126 |
| 2025-11-0416:12 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-264707 |
| 2025-10-3008:30 ET | 8-K | 8.01 Other events | 0001193125-25-257538 |
| 2025-09-0816:15 ET | 8-K | 8.01 Other events | 0000950170-25-113553 |
| 2025-08-1808:30 ET | 8-K | 8.01 Other events | 0000950170-25-109570 |
| 2025-08-0618:21 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-103290 |
| 2025-08-0516:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-103026 |
| 2025-07-3116:15 ET | 8-K | 8.01 Other events | 0000950170-25-100918 |
| 2025-07-1116:46 ET | 8-K | 8.01 Other events | 0000950170-25-095334 |
| 2025-07-0916:30 ET | 8-K | 8.01 Other events | 0000950170-25-094806 |
| 2025-06-2708:15 ET | 8-K | 8.01 Other events | 0000950170-25-090616 |
| 2025-05-1917:03 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-074529 |
| 2025-05-0718:09 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-064726 |
| 2025-05-0616:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-064473 |
| 2025-03-2817:00 ET | DEF 14A | Proxy statementPeriod 2025-05-15 | 0001308179-25-000296 |
| 2025-02-1916:58 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-023312 |
| 2025-02-1316:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-019854 |
| 2025-01-1308:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-004587 |
| 2024-12-1916:17 ET | 8-K | 8.01 Other events | 0000950170-24-138467 |
| 2024-12-1908:30 ET | 8-K | 8.01 Other events | 0000950170-24-138250 |
| 2024-11-1206:03 ET | 8-K | 8.01 Other events | 0000950170-24-124458 |
| 2024-11-0618:16 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-121679 |
| 2024-11-0516:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-121459 |
| 2024-10-0708:15 ET | 8-K | 8.01 Other events | 0000950170-24-113085 |
| 2024-10-0316:34 ET | 8-K | 8.01 Other events | 0000950170-24-112402 |
| 2024-08-0218:08 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-089488 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 14:15 ET. Listed shows no prices and gives no investment advice.